News - Antibiotics and Infectious diseases


Popular Filters

190 to 214 of 234 results

Astellas pulls out of deal with Theravance


Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

European Medicines Agency releases adverse reaction report


European Ombudsman Nikiforos Diamandouros has welcomed the European Medicines Agency's release of adverse…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulation

Zydus Cadila acquires Mumbai-based Biochem


Indian drug firm Zydus Cadila says it has acquired a 100% stake in Biochem, described as one of the top…

Antibiotics and Infectious diseasesAsia-PacificBiochemGenericsMergers & AcquisitionsZydus Cadila

Astellas and Optimer’s C. difficile drug cleared in Europe


Following an earlier positive recommendation from a European Medicines Agency advisory panel (The Pharma…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirEuropeOptimer PharmaceuticalsPharmaceuticalRegulation

TaiGen gets global nemonoxacin rights


Taiwan’s TaiGen Biotechnology has reached a deal with Ireland-headquartered Warner Chilcott (Nasdaq:…

Antibiotics and Infectious diseasesBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyWarner Chilcott

Backing for Japanese approval of Regnite, Ranmark and Cancidas


USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

New compound defeats drug-resistant bacteria


Bacteria can use efflux pumps to rid themselves of antibiotics, becoming drug-resistant until newer antibiotics…

Antibiotics and Infectious diseasesMPEX PharmaceuticalsPharmaceuticalResearch

World antibacterials market to grow to $43.8 billion in 2016, says Visiongain


World revenues for antibacterial drugs will reach $43.81 billion in 2016. Between 2010 and 2022, the…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

Key hospital-infections markets set to grow to over $4 billion in 2020; report


Despite market constraints that include intensified competition, generic erosion and an increasingly…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

EU Commission unveils 12 concrete actions against antimicrobial resistance for the next five years


With about 25,000 patients dying per year in the European Union from infections caused by drug resistant…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulationResearch

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases


Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

US hospital pharmacy and therapeutics committees decision-making process for antibiotics and antifungal therapies


In addition to managing the hospital’s anti-infective formulary, hospital pharmacy and therapeutics…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingNorth AmericaPharmaceutical

US FDA should require Black Box warning for Pfizer’s antibiotic Tygacil, says Public Citizen


US advocacy group Public Citizen has sent a petition to the Food and Drug Administration calling on the…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

EFPIA supports a new R&D model to tackle antimicrobial resistance


A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance,…

Antibiotics and Infectious diseasesEuropePharmaceuticalPoliticsResearch

Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy


US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news


UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Akorn in up to $58 million deal to acquire certain assets of India’s Kilitch Drugs and NBZ Pharma


US niche generics maker Akorn (Nasdaq: AKRX) has entered into an agreement to acquire certain assets…

AkornAntibiotics and Infectious diseasesAsia-PacificGenericsKilitch DrugsMergers & AcquisitionsOncologyOphthalmics

Inconclusive Ph III results for Pfizer’s Vfend and Eraxis combo in fungal infections


There was disappointing news for global drugs behemoth Pfizer (NYSE: PFE) last Friday, when the company…

Antibiotics and Infectious diseasesEraxisPfizerPharmaceuticalResearchVfend

More news from EMA/CHMP September meeting


Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA


The European Commission has granted marketing authorization for Japanese drug major Astellas’ (TYO:…

Antibiotics and Infectious diseasesAstellas PharmaEuropePharmaceuticalRegulationTheravanceVibativ

Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report


Less than half of surveyed infectious disease (ID) specialists and only 6% of surveyed internists demonstrated…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalVancocin

EU launches development and cooperation projects with South Africa, including AIDS and TB


European Development Commissioner Andris Piebalgs is visiting South Africa from September 13 to 16 to…

Anti-viralsAntibiotics and Infectious diseasesEuropeFinancialHealthcarePharmaceuticalRest of the World

GlaxoSmithKline partners with BARDA to develop new class of antibiotic; amends deal with Anacor


The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority…

Anacor PharmaceuticalAntibiotics and Infectious diseasesFinancialGlaxoSmithKlineLicensingPharmaceuticalResearchTropical diseases

190 to 214 of 234 results

Back to top